文献速递支持与姑息治疗

Guadecitabine治疗初治老年急性髓系白血病:多中心随机1/2期试验2期结果

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
PubMed 文献 · Lancet Oncol · 2017-08-24

这项多中心随机开放标签1/2期试验的2期部分纳入107例≥65岁不适合强化化疗的初治急性髓系白血病患者,比较guadecitabine 60或90 mg/m2 5天方案及60 mg/m2 10天方案的疗效与安全性。各剂量和方案组的复合完全缓解率无差异,最常见≥3级不良事件为发热性中性粒细胞减少和血小板减少。作者推荐的方案为60 mg/m2 5天方案。

要点

  • 60 mg/m2 5天组复合完全缓解13例(54%,95%CI 32.8-74.4),90 mg/m2 5天组16例(59%,38.8-77.6),60 mg/m2 10天组26例(50%,35.8-64.2)。
  • 5天方案发热性中性粒细胞减少31/51例(61%),10天方案36/52例(69%);血小板减少分别为25例(49%)和22例(42%)。
  • 65岁及以上不适合强化化疗的初治急性髓系白血病患者,推荐guadecitabine 60 mg/m2 5天方案。

核心结论

  • 超过一半的老年初治急性髓系白血病患者在所有研究的药物剂量和方案下均达到复合完全缓解,毒性可耐受。
  • 该人群推荐的guadecitabine方案为60 mg/m2 5天方案。
  • 一项针对该患者人群的3期研究正在进行(NCT02348489),评估guadecitabine 60 mg/m2 5天方案对比标准治疗。

研究设计与样本

  • 多中心、随机、开放标签的1/2期试验,本文报告初治急性髓系白血病患者队列的2期结果。
  • 纳入14家美国医疗中心(医院和专科癌症诊所)≥65岁不适合强化化疗的初治急性髓系白血病患者。
  • 107例患者入组:54例接受5天方案(26例随机分配至60 mg/m2,28例分配至90 mg/m2),53例分配至10天方案。
  • 随机分配采用计算机算法(动态随机化)按1:1进行,治疗分配未设盲;方案修订后额外分配患者至60 mg/m2 10天方案。
  • 主要终点为复合完全缓解(完全缓解、完全缓解伴血小板未完全恢复、或完全缓解伴中性粒细胞未完全恢复 regardless of platelets)。

主要发现

  • 中位年龄77岁(范围62-92),中位随访953天(IQR 721-1040)。
  • 复合完全缓解:60 mg/m2 5天组13例(54%,95%CI 32.8-74.4),90 mg/m2 5天组16例(59%,95%CI 38.8-77.6),60 mg/m2 10天组26例(50%,95%CI 35.8-64.2),组间无差异。
  • 最常见≥3级不良事件(不论与治疗关系):发热性中性粒细胞减少5天方案31/51例(61%)vs 10天方案36/52例(69%);血小板减少25例(49%)vs 22例(42%);中性粒细胞减少20例(39%)vs 18例(35%);肺炎15例(29%)vs 19例(37%);贫血15例(29%)vs 12例(23%);脓毒症8例(16%)vs 14例(27%)。
  • 最常见严重不良事件(不论与治疗关系)5天方案 vs 10天方案:发热性中性粒细胞减少27例(53%)vs 25例(48%);肺炎14例(27%)vs 16例(31%);脓毒症8例(16%)vs 14例(27%)。
  • 23例(22%)患者因不良事件死亡(主要为脓毒症8例[8%]和肺炎5例[5%]);4例死亡为治疗相关不良事件(肺炎2例[2%]、多器官衰竭1例[1%]、脓毒症1例[1%],均在10天队列)。

关键数值与推荐

  • 复合完全缓解定义:完全缓解、完全缓解伴血小板未完全恢复、或完全缓解伴中性粒细胞未完全恢复 regardless of platelets。
  • 推荐用于该人群的guadecitabine方案:60 mg/m2 5天方案,28天治疗周期。

临床怎么用

  • 作者认为,对于≥65岁不适合强化化疗的初治急性髓系白血病患者,guadecitabine 60 mg/m2 5天方案是推荐方案。
  • 作者指出,一项3期研究正在进行,以评估guadecitabine 60 mg/m2 5天方案对比标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The hypomethylating drugs azacitidine and decitabine have shown efficacy in myelodysplastic syndromes and acute myeloid leukaemia, but complete tumour responses are infrequent and of short duration, possibly because of the short half-lives and suboptimal bone marrow exposure of the drugs. Guadecitabine, a next-generation hypomethylating drug, has a longer half-life and exposure than its active metabolite decitabine. A phase 1 study established 60 mg/m2 guadecitabine for 5 days as an effective treatment schedule. In this phase 2 study, we aimed to assess the safety and activity of two doses and schedules of guadecitabine in older (≥65 years) patients with treatment-naive acute myeloid leukaemia who were not candidates for intensive chemotherapy. METHODS: We did a multicentre, randomised, open-label, phase 1/2 study of guadecitabine in cohorts of patients with treatment-naive acute myeloid leukaemia, relapsed or refractory acute myeloid leukaemia, and myelodysplastic syndromes; here we report the phase 2 results from the cohort of treatment-naive patients with acute myeloid leukaemia. We included patients aged at least 65 years from 14 US medical centres (hospitals and specialist cancer clinics) who were not candidates for intensive chemotherapy and randomly assigned them (1:1) using a computer algorithm (for dynamic randomisation) to guadecitabine 60 or 90 mg/m2 on days 1-5 (5-day schedule) of a 28-day treatment cycle. Treatment allocation was not masked. We also assigned additional patients to guadecitabine 60 mg/m2 in a 10-day schedule in a 28-day treatment cycle after a protocol amendment. The primary endpoint was composite complete response (complete response, complete response with incomplete platelet recovery, or complete response with incomplete neutrophil recovery regardless of platelets). Response was assessed in all patients (as-treated) who received at least one dose of guadecitabine. We present the final analysis, although at the time of the database lock, 15 patients were still in follow-up for overall survival. This study is registered with ClinicalTrials.gov, number NCT01261312. FINDINGS: Between Aug 24, 2012, and Sept 15, 2014, 107 patients were enrolled: 54 on the 5-day schedule (26 randomly assigned to 60 mg/m2 and 28 to 90 mg/m2) and 53 were assigned to the 10-day schedule. Median age was 77 years (range 62-92), and median follow-up was 953 days (IQR 721-1040). All treated patients were assessable for a response. The number of patients who achieved a composite complete response did not differ between dose groups or schedules (13 [54%, 95% CI 32·8-74·4] with 60 mg/m2 on the 5-day schedule; 16 [59%; 38·8-77·6] with 90 mg/m2 on the 5-day schedule; and 26 [50%, 35·8-64·2] with 60 mg/m2 on the 10-day schedule). The most frequent grade 3 or worse adverse events, regardless of relationship to treatment, were febrile neutropenia (31 [61%] of 51 patients on the 5-day schedule vs 36 [69%] of 52 patients on the 10-day schedule), thrombocytopenia (25 [49%] vs 22 [42%]), neutropenia (20 [39%] vs 18 [35%]), pneumonia (15 [29%] vs 19 [37%]), anaemia (15 [29%] vs 12 [23%]), and sepsis (eight [16%] vs 14 [27%]). The most common serious adverse events, regardless of relationship to treatment, for the 5-day and 10-day schedules, respectively, were febrile neutropenia (27 [53%] vs 25 [48%]), pneumonia (14 [27%] vs 16 [31%]), and sepsis (eight [16%] vs 14 [27%]). 23 (22%) patients died because of adverse events (mainly from sepsis, eight [8%]; and pneumonia, five [5%]); four deaths were from adverse events deemed treatment-related (pneumonia, two [2%]; multiorgan failure, one [1%]; and sepsis, one [1%], all in the 10-day cohort). INTERPRETATION: More than half of older treatment-naive patients with acute myeloid leukaemia achieved a composite complete response with guadecitabine at all drug doses and schedules investigated, with tolerable toxicity. The recommended guadecitabine regimen for this population is 60 mg/m2 in a 5-day schedule. A phase 3 study in this patient population is ongoing (NCT02348489) to assess guadecitabine 60 mg/m2 in a 5-day schedule versus standard of care. FUNDING: Astex Pharmaceuticals and Stand Up To Cancer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kantarjian HM, Roboz GJ, Kropf PL, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017. PMID: 28844816. doi:10.1016/S1470-2045(17)30576-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。